Editor's Note
FDA announced a new Dietary Supplement Ingredient Advisory List , a rapid-response tool designed to quickly alert the public when the FDA identifies ingredients that do not appear to be lawfully marketed in dietary supplements. The announcement came on the same day FDA sent 11 warning letters to companies for products marketed as dietary supplements and labeled to contain DMHA or phenibut.

In a press release, FDA highlighted its reaffirmed commitment to strengthen the regulation and oversight of dietary supplements through traditional advisory and enforcement actions like warning letters and the new tools like the Advisory List . Ingredients are added to the List based on a preliminary assessment by the FDA. The List enables the FDA to communicate with the public while it completes a final determination regarding these ingredients. The List is not exhaustive and will be updated.

"Consumers may wish to avoid buying and using products marketed as dietary supplements containing ingredients on this List, and industry may wish to avoid making or selling products marketed as dietary supplements containing these ingredients," FDA stated in a press release.
April 16, 2019
Food and Drug Administration

Today, the FDA unveiled its new  Dietary Supplement Ingredient Advisory List  , a rapid-response tool meant to quickly alert the public when the FDA identifies ingredients that do not appear to be lawfully marketed in dietary supplements. Consumers may wish to avoid buying and using products marketed as dietary supplements containing ingredients on this List, and industry may wish to avoid making or selling products marketed as dietary supplements containing these ingredients.

Ingredients are added to the Dietary Supplement Ingredient Advisory List based on a preliminary assessment by the FDA. The Dietary Supplement Ingredient Advisory List enables the FDA to communicate with the public while it completes a final determination regarding these ingredients. The List is not exhaustive and will be updated as ingredients are added to or removed from it. The FDA welcomes additional feedback and information, including information that may support or refute the FDA’s preliminary assessment, regarding the ingredients on the List. The FDA intends to communicate separately at any time that it identifies safety concerns about dietary ingredients or dietary supplements.

The FDA encourages individuals with questions about dietary supplements to  Submit an Inquiry , or to visit  www.fda.gov/fcic  for additional information.

Additional Information: